Treatment of Stage II Colon Cancer

Primary Surgical Management

The American Society of Clinical Oncology recommends surgery with wide resection and adequate lymph node sampling as the primary treatment for stage II colon cancer, with adjuvant chemotherapy reserved for specific high-risk subgroups rather than routine use 1, 2, 3
The European Society for Medical Oncology suggests that all stage II colon cancer patients require wide surgical resection as the definitive treatment 4
Colectomy with en bloc removal of regional lymph nodes, including at least 5 cm margins on either side of the tumor, is recommended 4
Examination of at least 12 lymph nodes is necessary to properly stage the disease and avoid under-staging 4, 5

The American Joint Committee on Cancer states that stage II disease is NOT a homogeneous entity—approximately 80% are cured by surgery alone 1, 4
Patients with stage IIA (T3) tumors who have all of the following features should NOT receive adjuvant chemotherapy: at least 12 lymph nodes examined, no perineural invasion, no lymphovascular invasion, well or moderately differentiated tumor grade, no intestinal obstruction, no tumor perforation, and less than grade BD3 tumor budding 1, 2, 6, 7

The National Comprehensive Cancer Network recommends that MMR/microsatellite instability (MSI) status be assessed before making chemotherapy decisions 1, 2, 6
For MMR-Proficient (pMMR) or Microsatellite Stable (MSS) Tumors, fluoropyrimidine monotherapy is the standard approach for most high-risk stage II patients 1, 2, 8
6 months of fluoropyrimidine-based chemotherapy (5-FU/leucovorin or capecitabine) is recommended for high-risk stage II patients 7, 8

Complete surgical resection with ≥12 lymph nodes examined is necessary for accurate staging and treatment planning 4, 5
Assessing MMR/MSI status on all stage II tumors is crucial for determining the need for adjuvant chemotherapy 1, 6
Identifying high-risk features, such as fewer than 12 lymph nodes examined, perineural invasion, lymphovascular invasion, poorly differentiated or undifferentiated histology, grade BD3 tumor budding, intestinal obstruction, and tumor perforation, is essential for determining the need for adjuvant chemotherapy 1, 2, 6
Applying treatment based on risk stratification, including observation only for low-risk patients, fluoropyrimidine-based chemotherapy for high-risk patients, and oxaliplatin-based chemotherapy for patients with multiple high-risk features, is recommended 1, 2, 6, 8